Holen Sie sich die Stockscreener-App
12.62
1.50%
0.182
Nurix Therapeutics Inc Aktie (NRIX) Neueste Nachrichten
Analysts Conflicted on These Healthcare Names: Align Tech (ALGN), Nurix Therapeutics (NRIX) and Thermo Fisher (TMO) - The Globe and Mail
Nurix Therapeutics (NRIX) to Participate in Key Oppenheimer Conf - GuruFocus
Nurix Therapeutics (NRIX) to Participate in Key Oppenheimer Conference | NRIX Stock News - GuruFocus
NuCana (NRIX) to Participate in Key Oppenheimer Conference | NRIX Stock News - GuruFocus
(NRIX) Investment Analysis - news.stocktradersdaily.com
Nurix Therapeutics (NASDAQ:NRIX) Trading Down 5.9%Here's What Happened - MarketBeat
Nurix Therapeutics’ SWOT analysis: promising BTK degrader stock faces challenges - Investing.com Nigeria
Nurix Therapeutics’ SWOT analysis: promising BTK degrader stock faces challenges By Investing.com - Investing.com South Africa
Nurix Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Nurix Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | NRIX Stock News - GuruFocus
Nurix Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) - MarketScreener
Nurix Therapeutics, Inc. (NASDAQ:NRIX) Receives $30.18 Average PT from Brokerages - MarketBeat
Nurix Therapeutics (NRIX) Shares Dip After Trial Update on Bexob - GuruFocus
Nurix stock drops on new trial data for lead drug (NRIX:NASDAQ) - Seeking Alpha
Transcript : Nurix Therapeutics, Inc.Special Call - MarketScreener
Nurix Therapeutics Announces Positive Phase 1 Trial Results - TipRanks
NRIX: Promising Data from Nurix's Bexobrutideg Clinical Trial | - GuruFocus
NRIX: Promising Data from Nurix's Bexobrutideg Clinical Trial | NRIX Stock News - GuruFocus
Nurix Therapeutics Presents Updated Positive Data Demonstrating Durable, Deepening Responses in Ongoing Clinical Trial of Bexobrutideg (NX-5948) Monotherapy in Patients with Relapsed/Refractory Chroni - GuruFocus
Nurix Therapeutics Presents Updated Positive Data Demonstrating Durable, Deepening Responses in Ongoing Clinical Trial of Bexobrutideg (NX-5948) Monotherapy in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL) and Waldenströ - The Manila Times
Breakthrough: Nurix Cancer Drug Achieves Complete Response in Hard-to-Treat Blood Cancers, New Trial Data Shows - Stock Titan
Nurix Therapeutics reports new KLHDC2 inhibitors - BioWorld MedTech
Truist Financial Sticks to Its Buy Rating for Nurix Therapeutics (NRIX) - The Globe and Mail
Nurix Therapeutics, Inc. to Discuss Data from the Ongoing Phase 1 Clinical Trial of Bexobrutideg Being Presented At the 30Th European Hematology Association Congress - marketscreener.com
Nurix Therapeutics to Host a Webcast Conference Call to Discuss - GuruFocus
Nurix Therapeutics to Host a Webcast Conference Call to Discuss Data from the Ongoing Phase 1 Clinical Trial of Bexobrutideg (NX-5948) Being Presented at the 30th European Hematology Association Congress (EHA2025) - The Manila Times
Nurix Therapeutics to Host a Webcast Conference Call to Discuss Data from the Ongoing Phase 1 Clinical Trial of Bexobrutideg (NX-5948) Being Presented at the 30th European Hematology Association Congr - GuruFocus
Nurix Therapeutics to Host Webcast on Phase 1 Clinical Trial Data for Bexobrutideg (NX-5948) at EHA2025 - Nasdaq
Nurix Therapeutics to Host a Webcast Conference Call to Discuss Data from the Ongoing Phase 1 ... - Bluefield Daily Telegraph
Bexobrutideg Phase 1 Trial Shows Promise in Blood Cancer Treatment at EHA Congress | NRIX Stock News - Stock Titan
Nurix Therapeutics (NASDAQ:NRIX) Shares Gap UpHere's Why - MarketBeat
Stifel Maintains Buy Rating on Nurix (NRIX) Stock - MSN
Nurix Therapeutics (NRIX) Moves 14.2% Higher: Will This Strength Last? - MSN
Nurix Therapeutics, Inc. (NASDAQ:NRIX) Shares Bought by Two Sigma Investments LP - MarketBeat
(NRIX) On The My Stocks Page - news.stocktradersdaily.com
Nurix Therapeutics, Inc. (NASDAQ:NRIX) Stock Position Reduced by Nuveen Asset Management LLC - MarketBeat
Sanofi exercises option to license STAT6 program from Nurix collaboration - BioWorld MedTech
Nurix Therapeutics Stock Climbs as Sanofi Extends License for STAT6 - marketscreener.com
Sanofi Exercises Exclusive License for Nurix Therapeutics' STAT6 Program - marketscreener.com
Sanofi Exercises License Extension Option To Nurix'S Stat6 Program - marketscreener.com
Sanofi Expands Rare Immunology Portfolio With Blueprint Buyout - Benzinga
Sanofi Licenses Nurix's STAT6 Program, Enhancing Drug Collaborat - GuruFocus
Sanofi Licenses Nurix's STAT6 Program, Enhancing Drug Collaboration | NRIX Stock News - GuruFocus
Sanofi Exercises License Extension Option to Nurix's STAT6 Program | NRIX Stock News - GuruFocus
Nurix secures additional $15 million from Sanofi license deal - Investing.com
Nurix Therapeutics Secures $15 Million License Extension from Sanofi for STAT6 Program - Nasdaq
Sanofi Bets Big on Nurix: $465M Deal for Revolutionary Inflammation Drug That Could Transform Asthma Treatment - Stock Titan
Nurix Therapeutics, Inc. (NASDAQ:NRIX) Shares Bought by Wellington Management Group LLP - MarketBeat
Nurix Therapeutics (NASDAQ:NRIX) Trading Up 3.9%Time to Buy? - MarketBeat
Millennium Management LLC Has $7.99 Million Stock Position in Nurix Therapeutics, Inc. (NASDAQ:NRIX) - MarketBeat
Twinbeech Capital LP Sells 35,683 Shares of Nurix Therapeutics, Inc. (NASDAQ:NRIX) - MarketBeat
Nurix Therapeutics to Participate in the Jefferies Global Health - GuruFocus
0.34%
7.69%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):